Announcements Trials
Browse Landscape

Status

Available 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 60Observational 1Expanded_access 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Carcinoma, Transitional Cell 1

Interventions

gallium 68 PSMA-11 4Magnetic Resonance Spectroscopy 4Abiraterone Acetate 3carbon-11 acetate 2Prednisone 2Prednisolone 2Axitinib 22-(3-(1-carboxy-5-((6-fluoropyridine-3-carbonyl)amino)pentyl)ureido)pentanedioic acid 2zenocutuzumab 1ulixertinib 1trametinib 1tempol 1tazemetostat 1talazoparib 1radium Ra 223 dichloride 1pegilodecakin 1omburtamab I-131 1niraparib 1neratinib 1motexafin gadolinium 1enfortumab vedotin 1dodecyl maltoside 1bicalutamide 1bemarituzumab 1balstilimab 1atezolizumab 1apalutamide 1TEMPOL-H 1Suspensions 1Sunitinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Expanded_access × Mitomycin × Genitourinary × Clear all
NCT05494411 2025-02-28

Named Patient Program for Mitomycin for Pyelocalyceal Solution

UroGen Pharma Ltd.

Available
Genitourinary

Carcinoma, Transitional Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡